The AHA Tuesday responded to a Centers for Medicare & Medicaid Services request for information regarding whether the agency should include exceptions to the electronic prescribing of controlled substances requirements in the Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act.

The comments also respond to CMS’ question of whether it should impose penalties for noncompliance.

“While we do not oppose the general requirement for prescriptions for Schedule II-V controlled substances to be transmitted electronically, we are concerned with the timeline proposed for implementation as well as the potential for penalties for noncompliance within this timeline,” the AHA said. It urged CMS to approach the requirement “based on a holistic view of the full range of federal regulations that require hospital IT development, upgrade, testing and end-user training, and proceed with a period of enforcement discretion and lack of penalties.”

Related News Articles

Headline
In an effort to reduce regulatory burden, the Food and Drug Administration will not require developers to submit a premarket approval application,…
Headline
The Department of Health and Human Services’ Office for Civil Rights yesterday alerted health care organizations to postcards disguised as official OCR…
Headline
The Centers for Medicare & Medicaid Services seeks input on rulemaking to require electronic prescribing for controlled substances covered by Medicare Part…
Headline
The House of Representatives last night voted 233-188 along party lines to pass a $1.5 trillion bill (H.R. 2) introduced by Democratic leaders to rebuild…
Headline
Regular surveys and reviews by The Joint Commission will resume this month, the commission announced last week. TJC, which had suspended surveys during the…
Headline
The Department of Health and Human Services Tuesday reminded health care providers that HIPAA privacy rules bar them from giving media and film crews access to…